Opinion|Videos|November 20, 2023

Treatment Approaches for Patients With EGFR-Mutant NSCLC

Author(s)Misako Nagasaka, MD, PhD, Sai-Hong Ou, MD, PhD, Janellen Smith, MD

Dr Sai-Hong Ou and Dr Misako Nagasaka discuss the treatment strategies for EGFR-mutant non-small cell lung cancer, emphasizing the importance of individualized decision making and a multidisciplinary approach.

Episodes in this series

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 1 Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 2 Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 3 Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 4 Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 5 Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 6 Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 7 Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

EP. 13 Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.

September 20th, 2026

Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.

Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

September 18th, 2026

Subcutaneous Amivantamab Combo is a “Clear” New Standard in EGFR+ NSCLC

Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

3D Rendered Medical Illustration of Male Anatomy - Lung Cancer. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

September 17th, 2026

PD-1/VEGF Bispecific Antibody Receives FDA Fast Track Designation in NSCLC

Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.

KST-6051 Receives Fast Track Designation in KRAS-Mutant Solid Tumors: © barinovalena - stock.adobe.com

September 17th, 2026

KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors

The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.

FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC

September 17th, 2026

FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC

Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.

Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.

September 17th, 2026

Subcutaneous Amivantamab Cuts Infusion Time in NSCLC Care

Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.

Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.

September 16th, 2026

PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data

Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.

The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.

September 16th, 2026

Novel Macrocyclic EGFR TKI Shows Responses in EGFR C797S–Positive NSCLC

The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.

Trending on CancerNetwork

Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC

Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma

Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC

FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer

FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC